Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,271 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,666 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06419179 | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)(GUIDANCE) | enrolling by invitation | Phase 2 | 29 | University of Cologne |
| 1 |
| May 20, 2025 |
| clinicaltrials |
| NCT06967662 | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)(INTRACOR_pilot) | enrolling by invitation | N/A | 28 | Ilyinskaya Hospital, JSCOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06261190 | Active Surveillance for Low-risk Papillary Thyroid Carcinoma(MAeSTro-EXP) | enrolling by invitation | — | 499 | National Cancer Center, KoreaOTHER_GOV | 1 | May 11, 2025 | clinicaltrials |
| NCT06931808 | Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer | enrolling by invitation | Phase 4 | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06715501 | Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06852144 | PET-TC in Thyroid Evaluation(PEPATI-MN-2024) | enrolling by invitation | — | 418 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06821490 | Validation of TAD in HER-2 with More Than 2 Lymph Nodes(DAD-HER2) | enrolling by invitation | — | 21 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06816966 | Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC(CISART) | enrolling by invitation | Phase 2 | 35 | Fujian Medical University Union HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | enrolling by invitation | Phase 2 | 37 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04755517 | Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)(HPV400) | enrolling by invitation | N/A | 14,000 | Tampere University HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06647836 | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma | enrolling by invitation | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730477 | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma | enrolling by invitation | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06712017 | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China | enrolling by invitation | — | 100 | GrandPharma (China) Co., Ltd.INDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06705049 | Retrospective Study on Leptomeningeal Metastasis of Solid Tumors | enrolling by invitation | — | 107 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05376553 | Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | enrolling by invitation | Phase 1 | 24 | Krzysztof MisiukiewiczOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06646263 | Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies | enrolling by invitation | — | 150 | Institute of Applied BiosciencesOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06647264 | A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery | enrolling by invitation | — | 1,500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04793633 | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer | enrolling by invitation | — | 500 | Adenocyte, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06048926 | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | enrolling by invitation | — | 6,750 | Novo Nordisk A/SINDUSTRY | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT03474237 | A Prospective Cohort Study for Patients With Adrenal Diseases | enrolling by invitation | — | 1,500 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 12, 2025source: clinicaltrials